Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary Legend Biotech Corporation (NASDAQ: LEGN) has appointed Dr. Fangliang Zhang, Dr. Li Mao, and Mr. Tomas J. Heyman to the Company’s Board of Directors, effective as of August 2, 2022. Dr. Zhang, Dr. Mao, and Mr. Heyman will serve as Class II, Class III, and Class I directors, respectively. Dr. Zhang will also serve as Chairman of the Board.
Mr. Tomas J. Heyman
Mr. Heyman previously served as the President of Johnson & Johnson’s Corporate Venture Capital Group from 2015 to September 2019 and as the Global Head of Business Development for Johnson & Johnson’s Pharmaceutical Group from 1992 to 2015. He also served as Chief Executive Officer of Janssen Pharmaceutica N.V. from 2008 to 2016. Mr. Heyman has been a director of OptiNose, Inc. since December 2020, a director of Akero Therapeutics, Inc. since June 2020, and a director of Adagio Therapeutics Inc. since June 2021. He holds a Master of Law from the K.U. Leuven in Belgium and has completed post-graduate studies in International Law in Geneva, Switzerland, and business management at the University of Antwerp in Belgium.
Dr. Fangliang Zhang
Dr. Zhang has been a non-executive director of GenScript Biotech Corporation since May 2022 and was chairman and an executive director of GenScript from 2015 to 2020. He co-founded GenScript in 2002 and has been the director of various group companies. In 2015, Dr. Zhang founded Legend Biotech as a subsidiary of GenScript, expanding its business to include the research, manufacture, and commercialization of immunotherapy treatments. He served as Chairman of the Board from 2015 to November 2020 and as CEO from August 2020 to September 2020. Dr. Zhang holds a Ph.D. in biochemistry from Duke University, a Master’s degree from Nanjing University, and a Bachelor’s degree from the Chengdu Institute of Geology.
Dr. Li Mao
Dr. Mao currently serves as Chief Medical Officer for SciClone Pharmaceuticals, Inc., a position he has held since June 2022. Previously, he was Chief Medical Officer of Sino Biopharmaceutical Co., Ltd from May 2021 to June 2022, CEO of Livzon Bio from March 2021 to April 2021, and CEO of Xcovery Holdings, Inc. from November 2018 to March 2021. Dr. Mao also served as Senior Vice President and Chief Medical Officer of Betta Pharmaceuticals Co., Ltd from March 2018 to March 2021 and Vice President at Johnson & Johnson from June 2016 to February 2018. He was a Professor at the MD Anderson Cancer Center from 2004 to March 2009 and at the University of Maryland, Baltimore from March 2009 to June 2016. Dr. Mao holds a Medical Doctor’s degree from Nanjing Medical University and completed a postdoctoral fellowship in cancer genetics at the John Hopkins University School of Medicine.-Fineline Info & Tech
